Merck
CN
  • Assessing human variability in kinetics for exposures to multiple environmental chemicals: a physiologically based pharmacokinetic modeling case study with dichloromethane, benzene, toluene, ethylbenzene, and m-xylene.

Assessing human variability in kinetics for exposures to multiple environmental chemicals: a physiologically based pharmacokinetic modeling case study with dichloromethane, benzene, toluene, ethylbenzene, and m-xylene.

Journal of toxicology and environmental health. Part A (2015-03-19)
Mathieu Valcke, Sami Haddad
摘要

The objective of this study was to compare the magnitude of interindividual variability in internal dose for inhalation exposure to single versus multiple chemicals. Physiologically based pharmacokinetic models for adults (AD), neonates (NEO), toddlers (TODD), and pregnant women (PW) were used to simulate inhalation exposure to "low" (RfC-like) or "high" (AEGL-like) air concentrations of benzene (Bz) or dichloromethane (DCM), along with various levels of toluene alone or toluene with ethylbenzene and xylene. Monte Carlo simulations were performed and distributions of relevant internal dose metrics of either Bz or DCM were computed. Area under the blood concentration of parent compound versus time curve (AUC)-based variability in AD, TODD, and PW rose for Bz when concomitant "low" exposure to mixtures of increasing complexities occurred (coefficient of variation (CV) = 16-24%, vs. 12-15% for Bz alone), but remained unchanged considering DCM. Conversely, AUC-based CV in NEO fell (15 to 5% for Bz; 12 to 6% for DCM). Comparable trends were observed considering production of metabolites (AMET), except for NEO's CYP2E1-mediated metabolites of Bz, where an increased CV was observed (20 to 71%). For "high" exposure scenarios, Cmax-based variability of Bz and DCM remained unchanged in AD and PW, but decreased in NEO (CV= 11-16% to 2-6%) and TODD (CV= 12-13% to 7-9%). Conversely, AMET-based variability for both substrates rose in every subpopulation. This study analyzed for the first time the impact of multiple exposures on interindividual variability in toxicokinetics. Evidence indicates that this impact depends upon chemical concentrations and biochemical properties, as well as the subpopulation and internal dose metrics considered.

材料
货号
品牌
产品描述

Sigma-Aldrich
二氯甲烷, anhydrous, ≥99.8%, contains 40-150 ppm amylene as stabilizer
Sigma-Aldrich
二氯甲烷, suitable for HPLC, ≥99.8%, contains amylene as stabilizer
Sigma-Aldrich
二氯甲烷, contains 40-150 ppm amylene as stabilizer, ACS reagent, ≥99.5%
Sigma-Aldrich
二氯甲烷, HPLC Plus, for HPLC, GC, and residue analysis, ≥99.9%, contains 50-150 ppm amylene as stabilizer
Sigma-Aldrich
苯, anhydrous, 99.8%
Sigma-Aldrich
苯, ≥99.0%, ACS reagent
Sigma-Aldrich
苯, suitable for HPLC, ≥99.9%
Supelco
苯, analytical standard
Sigma-Aldrich
二氯甲烷, puriss. p.a., ACS reagent, reag. ISO, ≥99.9% (GC)
Supelco
苯, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
苯, puriss. p.a., reag. Ph. Eur., ≥99.7%
Supelco
二氯甲烷, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
二氯甲烷, ACS reagent, ≥99.5%, contains 40-150 ppm amylene as stabilizer
Sigma-Aldrich
间二甲苯, anhydrous, ≥99%
Supelco
二氯甲烷, analytical standard
Sigma-Aldrich
二氯甲烷, puriss., meets analytical specification of Ph. Eur., NF, ≥99% (GC)
Supelco
间二甲苯, analytical standard
Sigma-Aldrich
间二甲苯, ReagentPlus®, 99%
Sigma-Aldrich
二氯甲烷, ACS reagent, ≥99.5%, contains 40-150 ppm amylene as stabilizer
Sigma-Aldrich
间二甲苯, puriss. p.a., ≥99.0% (GC)
Supelco
二氯甲烷 溶液, certified reference material, 5000 μg/mL in methanol
Supelco
二氯甲烷, Selectophore, ≥99.5%
Sigma-Aldrich
大黄酸, technical grade
Sigma-Aldrich
大黄酸
Sigma-Aldrich
二氯甲烷, biotech. grade, 99.9%, contains 40-150 ppm amylene as stabilizer
Supelco
间二甲苯, Pharmaceutical Secondary Standard; Certified Reference Material